Brokerage Focus: Northeast Securities maintains a "buy" rating on Hutchmed (China) (00013), pointing out its wide product market space and the potential for continuous overseas expansion.
Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
Hehuang Pharmaceutical (00013) Company News Review: Phase II clinical trials of sevotinib combination therapy showed improvement in ORR
swhy: First initiated a "buy" rating on hutchmed (china) (00013) with a target price of 35.4 Hong Kong dollars
Hehuang Pharmaceutical (00013.HK): Focus on the small molecule field of fruquintinib to achieve overseas commercialization
Citi: Maintains 'buy' rating on hutchmed (china) (00013), target price reduced to 38.9 Hong Kong dollars
Huhuang Pharmaceutical (0013.HK): Overseas sales of furoquintinib exceeded expectations, and the innovation pipeline accelerated
Hutchison Whampoa (00013.HK): Continued progress in overseas sales
US stocks change: Hutchmed (China) rose more than 7% in pre-market trading. CMB International raised its target price for H shares and maintained a 'buy' rating.
Robust Sales and Expansion Potential Underpin Buy Rating for HUTCHMED
CMB International: Maintains a 'buy' rating for Hutchmed (China) (00013) with a target price increase to HKD35.61.
Hutchison Pharmaceutical (00013.HK): Hutchison Pharmaceutical's performance is in line with expectations, and overseas logic is gradually being implemented
Huhuang Pharmaceutical (0013.HK): Overall performance in the interim report was in line with expectations, overseas sales of furoquintinib exceeded expectations
Huhuang Pharmaceutical (00013.HK): Fruquintinib sales in the US exceed expectations, are catalytically intensive
Hehuang Pharmaceutical (0013.HK): Overseas commercialization of fruquintinib accelerates global innovation pipeline and continues to catalyze
HUTCHMED(13.HK):FRUQUINTINIB'S OVERSEAS SALES BEAT
Bocom intl: maintains a buy rating on hutchmed (china) (00013) with a target price of HKD 40.40.
HUTCHMED (China) Price Target Raised to $19.00/Share From $17.00 by Goldman Sachs
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19
Hehuang Pharmaceutical (00013.HK) 2024 Interim Report Review: Continued Growth Momentum, R&D Results Gradually Revealed